NEPG(SZ:000597) Xin Lang Cai Jing·2025-10-27 11:10Core Viewpoint - Northeast Pharmaceutical Group Co., Ltd. has adjusted the repurchase price of its 2022 restricted stock incentive plan from 2.716 yuan/share to 2.416 yuan/share due to the implementation of annual profit distributions for 2022, 2023, and 2024 [1][5]. Summary by Sections Adjustment Background - The repurchase price adjustment is triggered by three annual profit distributions from 2022 to 2024, with specific distributions being: - In May 2023, a cash dividend of 1 yuan per 10 shares was distributed, equating to 0.1 yuan per share based on a total share capital of 1.434 billion shares [2]. - In May 2024, a similar distribution was made based on a total share capital of 1.429 billion shares [2]. - In May 2025, another distribution was made based on a total share capital of 1.427 billion shares [2]. Adjustment Plan - The cumulative impact of the three profit distributions results in a total dividend of 0.3 yuan/share, calculated as follows: - Adjusted repurchase price (P) = Initial price (P0) - Total dividend (V) [3][4]. Specific Adjustment Process - The initial repurchase price was 2.716 yuan/share, and after deducting the cumulative dividend of 0.3 yuan/share, the new repurchase price is set at 2.416 yuan/share [4]. Compliance and Impact - The adjustment has undergone necessary internal approval processes and is confirmed to comply with relevant regulations, ensuring it does not materially affect the company's financial status or the implementation of the incentive plan [5]. - The adjustment is characterized as a routine technical adjustment following profit distributions, aimed at maintaining fairness and accuracy in the incentive plan [5]. Review of Incentive Plan - The 2022 restricted stock incentive plan was initiated in May 2022 and has undergone several phases, including: - Initial grant registration completed in July 2022, with 76.51 million shares granted [6]. - Reserve grant registration completed in November 2022, with 9.933 million shares granted [6]. - By March 2025, over 78 million shares had been released from restrictions [6]. - The adjustment reflects the company's meticulous management of the equity incentive mechanism, which helps to continuously align the interests of the core team with the company's long-term development [6].